Non-Destructive Post-Transplant Lymphoproliferative Disorder

MedGen UID:: 277429
•Concept ID:: C1335035
•: Disease or Syndrome

Synonyms:

Non-Destructive PTLD; Non-Neoplastic Post-Transplant Lymphoproliferative Disorder; Post-Transplant Lymphoproliferative Disorder, Early Lesion

Definition

A lymphoproliferative disorder arising as a result of post-transplant immunosuppression therapy. It is characterized by the lack of tissue destruction and the architectural preservation of the involved tissues. It includes two morphologic variants: plasmacytic hyperplasia and infectious mononucleosis-like lymphoproliferative disorders. [from NCI]

Term Hierarchy

GTR
MeSH

CClinical test, RResearch test, OOMIM, GGeneReviews, VClinVar

CROGVNon-Destructive Post-Transplant Lymphoproliferative Disorder

Disease
- Disorder by Site
  - Hematopoietic and Lymphoid System Disorder
    - Hematologic disorder
      - Lymphoproliferative disorder
        B-Cell Lymphoproliferative Disorder
        Non-Destructive Post-Transplant Lymphoproliferative Disorder
        Florid Follicular Hyperplasia Post-Transplant Lymphoproliferative Disorder
        Infectious mononucleosis-like post-transplant lymphoproliferative disorder
        Plasmacytic Hyperplasia Post-Transplant Lymphoproliferative Disorder

Professional guidelines

PubMed

Characteristics, management, and outcome of pediatric patients with post-transplant lymphoproliferative disease-A 20 years' experience from Austria.

Füreder A, Kropshofer G, Benesch M, Dworzak M, Greil S, Huber WD, Hubmann H, Lawitschka A, Mann G, Michel-Behnke I, Müller-Sacherer T, Pichler H, Simonitsch-Klupp I, Schwinger W, Szepfalusi Z, Crazzolara R, Attarbaschi A; Austrian Society of Pediatric Hematology and Oncology
Cancer Rep (Hoboken) 2021 Oct;4(5):e1375. Epub 2021 Mar 23 doi: 10.1002/cnr2.1375. PMID: 33755341 Free PMC Article

See all (1)

Recent clinical studies

Etiology

Programmed cell death ligand 1 expression associated with subtypes of post-transplant lymphoproliferative disorder among pediatric kidney transplant recipients.

Weinberg OK, Pinkus GC, Ramos-Gonzalez GJ, Agur T, Rodig NM
Clin Transplant 2023 Dec;37(12):e15134. Epub 2023 Sep 29 doi: 10.1111/ctr.15134. PMID: 37772613

Risk factors evaluation of post-transplant lymphoproliferative disorders after allogeneic haematopoietic stem cell transplantation with comparison between paediatric and adult.

Chen DB, Liu XY, Kong FZ, Jiang Q, Shen DH
J Clin Pathol 2021 Nov;74(11):697-703. Epub 2021 May 19 doi: 10.1136/jclinpath-2021-207492. PMID: 34011618

Characteristics, management, and outcome of pediatric patients with post-transplant lymphoproliferative disease-A 20 years' experience from Austria.

See all (3)

Diagnosis

Programmed cell death ligand 1 expression associated with subtypes of post-transplant lymphoproliferative disorder among pediatric kidney transplant recipients.

Weinberg OK, Pinkus GC, Ramos-Gonzalez GJ, Agur T, Rodig NM
Clin Transplant 2023 Dec;37(12):e15134. Epub 2023 Sep 29 doi: 10.1111/ctr.15134. PMID: 37772613

Characteristics, management, and outcome of pediatric patients with post-transplant lymphoproliferative disease-A 20 years' experience from Austria.

Post-transplant primary cutaneous peripheral T-cell lymphoma not otherwise specified in a pediatric patient.

Cardwell LA, Majerowski J, Chiu YE, Harrington AM, Sokumbi O
J Cutan Pathol 2021 May;48(5):706-712. Epub 2021 Mar 9 doi: 10.1111/cup.13967. PMID: 33476057

See all (3)

Therapy

Programmed cell death ligand 1 expression associated with subtypes of post-transplant lymphoproliferative disorder among pediatric kidney transplant recipients.

Weinberg OK, Pinkus GC, Ramos-Gonzalez GJ, Agur T, Rodig NM
Clin Transplant 2023 Dec;37(12):e15134. Epub 2023 Sep 29 doi: 10.1111/ctr.15134. PMID: 37772613

Risk factors evaluation of post-transplant lymphoproliferative disorders after allogeneic haematopoietic stem cell transplantation with comparison between paediatric and adult.

Chen DB, Liu XY, Kong FZ, Jiang Q, Shen DH
J Clin Pathol 2021 Nov;74(11):697-703. Epub 2021 May 19 doi: 10.1136/jclinpath-2021-207492. PMID: 34011618

Characteristics, management, and outcome of pediatric patients with post-transplant lymphoproliferative disease-A 20 years' experience from Austria.

Post-transplant primary cutaneous peripheral T-cell lymphoma not otherwise specified in a pediatric patient.

Cardwell LA, Majerowski J, Chiu YE, Harrington AM, Sokumbi O
J Cutan Pathol 2021 May;48(5):706-712. Epub 2021 Mar 9 doi: 10.1111/cup.13967. PMID: 33476057

Comparative analysis of post-transplant lymphoproliferative disorders after solid organ and hematopoietic stem cell transplantation reveals differences in the tumor microenvironment.

Overkamp M, Granai M, Bonzheim I, Steinhilber J, Schittenhelm J, Bethge W, Quintanilla-Martinez L, Fend F, Federmann B
Virchows Arch 2021 Jun;478(6):1135-1148. Epub 2020 Dec 15 doi: 10.1007/s00428-020-02985-4. PMID: 33324999 Free PMC Article

See all (5)

Prognosis

Programmed cell death ligand 1 expression associated with subtypes of post-transplant lymphoproliferative disorder among pediatric kidney transplant recipients.

Weinberg OK, Pinkus GC, Ramos-Gonzalez GJ, Agur T, Rodig NM
Clin Transplant 2023 Dec;37(12):e15134. Epub 2023 Sep 29 doi: 10.1111/ctr.15134. PMID: 37772613

Risk factors evaluation of post-transplant lymphoproliferative disorders after allogeneic haematopoietic stem cell transplantation with comparison between paediatric and adult.

Chen DB, Liu XY, Kong FZ, Jiang Q, Shen DH
J Clin Pathol 2021 Nov;74(11):697-703. Epub 2021 May 19 doi: 10.1136/jclinpath-2021-207492. PMID: 34011618

Characteristics, management, and outcome of pediatric patients with post-transplant lymphoproliferative disease-A 20 years' experience from Austria.

Comparative analysis of post-transplant lymphoproliferative disorders after solid organ and hematopoietic stem cell transplantation reveals differences in the tumor microenvironment.

See all (4)